Trials / Completed
CompletedNCT00347958
Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine
Safety Among Adolescents and Adults of Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®) 4 to 5 Years After a Previous Dose
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 545 (actual)
- Sponsor
- Sanofi Pasteur, a Sanofi Company · Industry
- Sex
- All
- Age
- 15 Years – 69 Years
- Healthy volunteers
- Accepted
Summary
Objectives: To provide safety data on revaccination with ADACEL® vaccine. To describe the immune response to tetanus, diphtheria, and pertussis antigens following revaccination with ADACEL® vaccine 4-5 years after first vaccination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Tetanus-diphtheria-acellular pertussis (Tdap) vaccine | 0.5mL, Intramuscular (IM) |
Timeline
- Start date
- 2006-08-01
- Primary completion
- 2008-02-01
- Completion
- 2008-10-01
- First posted
- 2006-07-04
- Last updated
- 2013-12-04
- Results posted
- 2010-07-22
Locations
10 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00347958. Inclusion in this directory is not an endorsement.